Thomas Rennard, MD
Family Medicine · Asheville, NCNPI 1346236809
Payments from drug & device makers
Across 102 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$396
- E.r. Squibb & Sons, L.L.C.$167
- Novartis$154
- Abbott$125
- Amgen$111
- Merck$90
- plus $796 from 25 others
What the payments were for
- Food & beverage$1,81399%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $396 |
| E.r. Squibb & Sons, L.L.C. | 10 | $167 |
| Novartis | 8 | $154 |
| Abbott | 5 | $125 |
| Amgen | 6 | $111 |
| Merck | 5 | $90 |
| AbbVie | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 6 | $81 |
| Dexcom, Inc. | 3 | $68 |
| Nevro Corp. | 3 | $57 |
| Pfizer | 3 | $53 |
| Amarin Pharma, Inc. | 2 | $44 |
| Novo Nordisk | 3 | $43 |
| Si-bone, Inc. | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Radius Health, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| GSK | 2 | $24 |
| Cequr Corporation | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Inari Medical, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $16 |
| Boston Scientific | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$1,840 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 407 | $306,150 |
| XareltoRivaroxaban | 196 | $163,737 |
| JardianceEmpagliflozin | 158 | $131,155 |
| MounjaroTirzepatide | 67 | $101,573 |
| OzempicSemaglutide | 60 | $76,223 |
| TivicayDolutegravir Sodium | 23 | $50,485 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $44,317 |
| Repatha SureclickEvolocumab | 53 | $33,037 |
| FarxigaDapagliflozin Propanediol | 27 | $29,682 |
| MyrbetriqMirabegron | 43 | $28,838 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,697 |
| ProliaDenosumab | 13 | $22,882 |
| LinzessLinaclotide | 34 | $21,811 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $15,286 |
| EntrestoSacubitril/Valsartan | 17 | $15,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $53 | $317,143435 claims |
| Johnson & JohnsonXarelto | $20 | $163,737196 claims |
| Novo NordiskOzempic | $43 | $76,22360 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $24 | $49,47256 claims |
| AbbVieLinzess, Synthroid | $86 | $31,057151 claims |
| AstraZenecaFarxiga | $11 | $29,68227 claims |
| Astellas Pharma US IncMyrbetriq | $396 | $28,83843 claims |
| AmgenProlia | $111 | $22,88213 claims |
| NovartisEntresto | $154 | $15,19717 claims |
| MerckJanuvia | $90 | $12,25622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Asheville
- Kimberly BaptisteAsheville$151K
- Jason CookAsheville$120K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.